eBC and mBC Treatment | KISQALI (ribociclib)
WEBKISQALI is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has gotten worse or has spread to other parts of the body (metastatic), in combination with:
Downloadable Resources | KISQALI® (ribociclib) | HCP
WEBAccess resource materials for health care professionals about 1L HR+/HER2- metastatic breast cancer and KISQALI treatment. See full Prescribing & Safety Info.
KISQALI
WEB/metastatic-breast-cancer
Breast cancer treatment: Drug Kisqali approval expanded for …
WEB5 days ago · In a phase 3 clinical trial from the drugmaker Novartis, Kisqali reduced the risk of a patient’s breast cancer coming back by 25% after three years when given in addition to standard treatments,...
How KISQALI® (ribociclib) Works
WEBLearn how KISQALI can work as a possible HR+, HER2- metastatic breast cancer treatment combined with hormone therapy. See full Prescribing & Safety Info.
Novartis: Kisqali Reduces Recurrence Risk By 28.5% In Late-stage …
WEB6 days ago · Kisqali, developed by Novartis under a research collaboration with Astex Pharmaceuticals, is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of...
Sign Up for Novartis Patient Support | KISQALI® (ribociclib)
WEBGet the help you need. It only takes a few minutes to get started. See all that can offer: ? Free Support Program. Get personalized support from your Novartis Patient Support Team. ? $0 Co-Pay Plus* offer. Privately insured? Pay as little as $0 with your Co-Pay Plus offer for KISQALI and/or FEMARA. ? Free Trial Offer†.
FDA expands approval of breast cancer drug Kisqali: What to …
WEB4 days ago · FDA expands approval of breast cancer drug Kisqali: What to know. The FDA expanded approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the...
Kisqali - European Medicines Agency (EMA)
WEBAug 31, 2017 · Kisqali is a cancer medicine used to treat breast cancer that is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body).
Novartis AG: Hold Rating Justified Amid Kisqali’s Market Potential …
WEB4 days ago · The FDA’s approval of Kisqali for use in early-stage breast cancer as an adjuvant therapy, with an extensive label covering stage II and III of the disease, marks a significant milestone for the...
- Some results have been removed
Skip to content
